Laborie Medical Technologies Corp.
$2.2M 3,675 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Mylan Pharmaceuticals Inc.
Mylan Pharmaceuticals Inc. reported $2,181,017.07 across General Payments, Research, and Ownership to 8 physicians and teaching hospitals across 37 transactions.
- $2.2M Top quartile payer
- All-tracks total
- 37 Below-median volume
- Transactions
- 8 Below-median reach
- Recipients
- #432
- of 1,925 companies
Mylan Pharmaceuticals Inc. reported $2,181,017.07 across all CMS Open Payments tracks (General + Research + Ownership) to 8 physicians and teaching hospitals in Program Year 2024 - ranking #432 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $379.70, averaging $272.6K per recipient.
How Mylan Pharmaceuticals Inc.'s $2.2M all-tracks total breaks down
Mylan Pharmaceuticals Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
30/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mylan-pharmaceuticals-inc Mylan Pharmaceuticals Inc.
$2.2M · #432/1,925 · 0.0% industry · PY2024
- TOT $2.2M
- RANK #432
- SHARE 0.0%
- TXN 37
- RCP 8
- CAT 1
- GEN $379.70
- TOP1 75.2%
- PY 2024
Volume peers
Nearest volume peer: Laborie Medical Technologies Corp. ($2.2M)
Mylan Pharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Mylan Pharmaceuticals Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Mylan Pharmaceuticals Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
8 transactions worth $379.70 make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, Mylan Pharmaceuticals Inc.'s largest category was "Food and Beverage" at $379.70 - 100.0% of General Payments.
How Mylan Pharmaceuticals Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $379.70 | 8 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $363.70 (95.8%) of $379.70 in this company's General Payments records across 6 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mylan Pharmaceuticals Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Maria CONCEICAO Martinslopes
$285.40 across 3 reported transactions
- 2
Daniel Robert Brune
$23.15 across 1 reported transactions
- 3
Daniel Brune
$23.15 across 1 reported transactions
- 4
John Untisz
$16.00 across 1 reported transactions
- 5
Darrell Nettlow
$16.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Mylan Pharmaceuticals Inc.'s spend rank (#432 of 1,925, top 22% by spend) and concentration rank (#276 of 1,838, top 15% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- ReShape Lifesciences Inc. : $5.8K total payments, HHI 5891
- Rebiotix Inc. : $114.1K total payments, HHI 5889
- Spark Therapeutics, Inc. : $1.1M total payments, HHI 5876
- Agile Devices, Inc. : $8.4K total payments, HHI 5847
- Hubly Incorporated : $205.53 total payments, HHI 5839
- New York Blood Center, Inc. : $184.6K total payments, HHI 5838
- Mylan Pharmaceuticals Inc. (this company) : $379.70 total payments, HHI 5777
- Novo Nordisk US Research & Development, Inc. : $7.8K total payments, HHI 5774
- Spinevision SAS : $66.0K total payments, HHI 5765
- Cook Medical LLC : $2.8M total payments, HHI 5718
- Channel Medsystems, Inc. : $194.3K total payments, HHI 5715
- Adagio Medical, Inc. : $49.5K total payments, HHI 5713
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mylan Pharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mylan Pharmaceuticals Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mylan Pharmaceuticals Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Akebia Therapeutics Inc
$2.2M 5,560 recipients
Compare payment profiles
SiteSaver Inc.
$2.2M 2 recipients
Compare payment profiles
Bluewind Medical
$2.2M 1,632 recipients
Compare payment profiles
Coherus Biosciences Inc.
$2.2M 2,945 recipients
Compare payment profiles
United Imaging Healthcare North America, Inc.
$2.2M 66 recipients
Compare payment profiles
Put this to use
Mylan Pharmaceuticals Inc. ranks #432 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Mylan Pharmaceuticals Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Mylan Pharmaceuticals Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.